Hong Dongsheng, Lv Duo, Wu Jiaying, Li Xin, Zhao Qingwei, Lu Xiaoyang, Li Lu
Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Department of Social Medicine of school of Public Health, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Risk Manag Healthc Policy. 2023 Sep 8;16:1781-1790. doi: 10.2147/RMHP.S418541. eCollection 2023.
DIP is a new medical insurance payment system developed in China which was implemented in Guangzhou in January 2018, but few studies have focused on its intervention effect on the drug burden of elderly hypertensive patients.
Nine medical institutions in Guangzhou, China, were selected, among which, daily full medical orders of elderly hypertensive inpatients from 2016 to 2020 were randomly collected. To assess the impact of DIP policy intervention on patient drug burden, we took the data after policy implementation in January 2018, as the intervention data, and applied a segmented regression model with interrupted time series to analyze the trend and changes in average daily drug costs per month and medication structure, stratified by age, sex, and inpatient department.
A total of 34,276 elderly hypertensive patients' daily full medical orders were obtained. The immediate level change of drug costs after intervention was -23.884 RMB/month ( = 0.652), and the trend change was statistically significant (-15.642 RMB/month, = 0.002). The relative cumulative effect at the end of the study was -78.860% (95% CI: -86.087% to -69.076%), and the intervention effect was more significant in surgical and male patients. The analysis of drug structure changes showed that after the implementation of the DIP policy intervention, the proportion of anti-infective drugs, anti-tumor drugs, and biological products all showed a significant downward trend ( < 0.05), while nutritional drugs showed a significant upward trend ( = 0.011), but no immediate horizontal change in slope was observed.
The typical practice in China showed that DIP policy intervention can improve the drug burden of elderly hypertensive hospitalized patients and has a stable long-term effect, and the intervention effect is not consistent across different clinical department and populations with different characteristics, and it would also cause changes in the medication structure.
疾病诊断相关分组(DIP)是我国新开发的一种医疗保险支付系统,于2018年1月在广州实施,但很少有研究关注其对老年高血压患者用药负担的干预效果。
选取中国广州的9家医疗机构,随机收集2016年至2020年老年高血压住院患者的每日完整医嘱。为评估DIP政策干预对患者用药负担的影响,我们将2018年1月政策实施后的数据作为干预数据,应用具有间断时间序列的分段回归模型,按年龄、性别和住院科室分层,分析每月平均每日药品费用和用药结构的趋势及变化。
共获得34276例老年高血压患者的每日完整医嘱。干预后药品费用的即时水平变化为-23.884元/月(P = 0.652),趋势变化具有统计学意义(-15.642元/月,P = 0.002)。研究结束时的相对累积效应为-78.860%(95%CI:-86.087%至-69.076%),干预效果在外科患者和男性患者中更为显著。药品结构变化分析表明,DIP政策干预实施后,抗感染药物、抗肿瘤药物和生物制品的比例均呈显著下降趋势(P < 0.05),而营养药物呈显著上升趋势(P = 0.011),但未观察到斜率的即时水平变化。
我国的典型实践表明,DIP政策干预可改善老年高血压住院患者的用药负担,且具有稳定的长期效果,不同临床科室和不同特征人群的干预效果不一致,还会导致用药结构发生变化。